Name: Cloud Gray Pty Ltd
Price range: $

Sponsored Symposia

Please indicate your attendance at the Sponsored Symposia at the time of registration. If you are already registered for the ASM and wish to attend a sponsored symposia, or have any questions, contact us via email at tsanzsrs@theconferencecompany.com.
If you have not yet registered for the ASM, you can register as part of the online registration form here.

Saturday, 22nd March 2025

Overview of the current and future treatments in Interstitial Lung Disease

Time: 6pm - 7.30pm

Synopsis: Boehringer Ingelheim aims for this informative session to explore the evolving landscape of interstitial lung disease (ILD). The suggested topic and agenda on this symposium will focus on providing an update on the current treatment landscape in ILD, highlighting the unmet clinical needs and future ILD treatments that may address these gaps.

Sunday, 23rd March 2025

More than meets the eosinophil: the evolving science of interleukin-5 in airway type-2 inflammation

Time: 7.15am -8.15am (breakfast served at 6.45am)

Speakers: Prof Gary Anderson, Prof Phil Bardin, Dr Angela Moran

Synopsis: Interleukin-5 (IL-5) is well known for its critical role in eosinophil generation, activation and survival, and therefore has been a therapeutic target in Type 2 inflammatory airways disease. This symposium aims to delve into the emerging evidence demonstrating multifaceted roles of IL-5 beyond its traditional understanding.

Hear from internationally renowned experts on the evidence demonstrating the potential impact IL-5 has on epithelial barrier integrity, immune cell dysfunction and airway remodelling, presented in the context of clinical practice and anti-IL-5 intervention in airways disease.

Join us for this enlightening symposium to stay at the forefront of IL-5 research and its transformative potential in managing Type 2 inflammatory diseases.

Inhale, Exhale, Innovate: Breathing Sustainability into Inhaler Design

Time: 7.15am -8.15am (breakfast served at 6.45am)

Chair: Prof Helen Reddel

Speakers: Prof John Blakey, Professor Christine Jenkins, Professor David Price

Synopsis: Understanding the aspects of respiratory medicine that contribute to climate change is a critical first step in mitigating emissions. Some actions can be taken by individuals whilst others must be taken by the pharmaceutical industry who have an obligation to invest in technology to lower the global warming potential of the propellants in currently available pMDIs (considered F-gases).

This session presents technologies and strategies to reduce carbon emissions in respiratory medicine while maintaining patient care and patient choice.

Prof John Blakey will cover the development of carbon-minimal inhalers, outlining the pathway from preclinical research to commercialisation and provide a review of current programs.

Prof. Christine Jenkins will address the environmental impact of SABA overuse, a major source of emissions in asthma treatment, and discuss clinical strategies to manage overuse, improve asthma control, and reduce environmental harm.

Finally, new research on Maintenance and Reliever Therapy (MART) will be presented by Prof David Price highlighting the potential for MART to reduce greenhouse gas emissions while maintaining asthma control.

The session aims to equip healthcare professionals with the tools to transition to high value, low carbon healthcare.